Tegoprazan in Gastroesophageal Reflux Disease and Related Acid-Mediated Conditions: A Systematic Review and Meta-Analysis.

JGH Open · 2026 · PMC13090113 · PMID 42006860

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

2023 [ 27 ] reported greater reductions in Reflux Symptom Index (RSI) and Reflux Finding Score (RFS) with Tegoprazan than with placebo after 4 and 8 weeks, although between‐group differences did not reach statistical significance because of small sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.